|
 
Technology Transfer Symposium:
Promoting Public-Private Collaboration for Innovation
The Symposium on Technology Transfer held at the BIO Investor Forum in October 2009 was well-received by attendees as an important first-step in collaborative discussions on technology transfer policy between universities, industry, and investor communities. BIO intends to host a similar event in conjunction with meetings at the BIO National Venture Conference in March 2010 in Boston, MA.
Symposium Sessions: Presentation Links
Session 1: Today’s Technology Transfer Policy Landscape
All Slides
Session 2: Economic Impact & Licensing Relationships between Universities & Industry
BIO 2009 Member Survey on Licensing
Session 2 - Lori Pressman
Session 2 - Ashley Stevens
Session 2 - David Roessner
Session 3: Unique & Creative Collaborative Mechanisms
Session 3 - Partial Slides
Session 3 - Lita Nelson
Session 3 - W. Mark Crowell
For more information and news, visit http://biotechtransfer.wordpress.com.
Understanding Technology Transfer
The U.S. leads the world in research and development of biotechnology products, due in large part to government support of basic research at universities. Government funding is awarded to top universities nationwide to sponsor research from the National Institutes of Health (NIH). Breakthroughs in basic research can lead to life-saving therapeutics through cooperative efforts of the public and private sectors. These efforts usually take the form of technology transfer agreements between NIH-funded institutions and biotechnology companies. In 1980, Congress approved The Bayh-Dole Act (see additional resources section).
In the past, discussions of "reasonable pricing" on NIH funded inventions upset the successful partnership between the private and public sector. Biotechnology companies need the freedom to license intellectual property in a manner that is beneficial to the public interest, and companies should not be hampered by price controls.
Additional Resources
- BIO Study Showing Industry/University Partnerships Critical to U.S. Economy (October 28, 2009)
Read the Press Release
Read the Study on Economic Benefits of Bayh-Dole Act
Read the Survey of Licensing Practices of BIO Member Companies
Read the Summary of Findings of Licensing Survey
- BIO Statement to the Secretary's Advisory Committee on Genetics Health & Society (October 8, 2009)
- GAO Report to Congress: Information on the Government’s Right to Assert Ownership Control over Federally Funded Inventions (July 2009)
- BIO Statement to the Secretary's Advisory Committee on Genetics, Health & Society (May 15, 2009)
- BIO Statement to the Senate Committee on the Judiciary on the Role of Federally-Funded University Research in the Patent System
(October 24, 2007) (438 KB PDF)
- BIO statement on the Bayh-Dole Act
(August 27, 2007) (78 KB PDF)
- Technology Transfer: Benefits from Biotech (July 10, 2007)
WGRI-2 Side-Event
- NIH: Moving Research From the Bench to the Bedside (July 10, 2003)
Testimony Before the Energy and Commerce Health Subcommittee of the U.S. House of Representatives
- Bayh-Dole and Technology Transfer (April 11, 2002)
Testimony Before the President's Council on Science and Technology
- Letter opposing use of Bayh-Dole march-in powers (May 24, 2004) (324 KB PDF)
- Statement Before the NIH Blue Ribbon Panel on Conflict of Interest Policies (April 16, 2004) (171 KB PDF)
- BIO letter to the editor of the Washington Post clarifying the Bayh-Dole Act (March 29, 2002) (66.3 KB PDF)
|
